Logo_Biofrontera_AG.png
Biofrontera Reports First Quarter 2019 Financial Results
29. Mai 2019 03:11 ET | Biofrontera AG
Leverkusen, Germany, May 29, 2019 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported its...
Logo_Biofrontera_AG.png
Biofrontera Announces Conference Call on May 29, 2019 to Discuss First Quarter 2019 Financial Results
16. Mai 2019 04:30 ET | Biofrontera AG
Leverkusen, Germany, May 16, 2019 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, will be releasing its...
Logo_Biofrontera_AG.png
Biofrontera Reports Full Year 2018 Financial Results
29. April 2019 02:00 ET | Biofrontera AG
Leverkusen, Germany, April 29, 2019 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported its...
Logo_Biofrontera_AG.png
Biofrontera AG to hold extraordinary shareholders’ meeting on 15 May 2019
26. April 2019 09:20 ET | Biofrontera AG
Leverkusen, Germany, April 26, 2019 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today announced in...
Logo_Biofrontera_AG.png
Biofrontera reports further positive results from the phase III trial with Ameluz® for photodynamic therapy of actinic keratoses on the extremities and trunk/neck
16. April 2019 07:30 ET | Biofrontera AG
Leverkusen, Germany, April 16, 2019 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reports...
Logo_Biofrontera_AG.png
Biofrontera Announces Conference Call on April 29, 2019 to Discuss 2018 Financial Results
16. April 2019 05:30 ET | Biofrontera AG
Leverkusen, Germany, April 16, 2019 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, will be releasing...
Logo_Biofrontera_AG.png
Biofrontera reports preliminary unaudited sales revenue for the first three months of 2019
15. April 2019 06:15 ET | Biofrontera AG
Leverkusen, Germany, April 15, 2019 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reports...
Logo_Biofrontera_AG.png
Biofrontera provides information on the announced voluntary public tender offer by Maruho Deutschland GmbH
02. April 2019 08:30 ET | Biofrontera AG
Leverkusen, Germany, April 02, 2019 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, informs about the...
Logo_Biofrontera_AG.png
Changes in the composition of the Supervisory Board
27. März 2019 09:05 ET | Biofrontera AG
Leverkusen, Germany, March 27, 2019 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, announces that the...
Logo_Biofrontera_AG.png
Biofrontera provides corporate update; conference call details for March 26, 2019
25. März 2019 11:30 ET | Biofrontera AG
Leverkusen, Germany, March 25, 2019 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, announces a...